Table 7.

Adverse event rates between the full cohort of this study (up to week 14) and the full TNF-failure cohort from the GEMINI 1 study (induction phase only, up to week 6).

	Korean study; full cohort	GEMINI 1 study; full TNF-failure cohort
	n = 105	n = 304
Safety outcomes
Any AE, n (%)	16 (15.2)	164 (53.9)
Any SAE, n (%)	5 (4.8)	12 (3.9)
Top 3 AEs in the current study
UC exacerbation (%)	6 (5.7)	11 (3.6)
Upper respiratory tract infection (%)	5 (4.8)	6 (2.0)
Arthralgia (%)	2 (1.9)	11 (3.6)

AE, adverse event; SAE, serious adverse event; TNF, tumor necrosis factor; UC, ulcerative colitis.